OHSU researchers identify promising next-generation cancer treatment
Chemistry discovery points to next generation inhibitors of PARP-1, a critical target in ovarian, breast and prostate cancers.
Related Articles
Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response
A vancomycin minimum inhibitory concentration >2 μg/mL in Clostridioides difficile was associated with decreased odds of 30-day sustained clinical respo
Central Falls breaks ground for a new $108 million high school – The Boston Globe
The new school, set to be completed at the end of 2025, will replace a nearly 100-year-old building beset by leaky roofs, balky boilers, mold,…
Lab mice might be doing their own experiments
New research suggests that mice base their decisions on more than just immediate reward. They may also make ‘mistakes’ on purpose.
A pan-cancer analysis of the microbiome in metastatic cancer
Characterization of microbiome genomes at the species level in over 4,000 metastatic tumor biopsies identifies the distribution and diversity features of tumor-resident bacterial DNA at…
Lab mice might be doing their own experiments
New research suggests that mice base their decisions on more than just immediate reward. They may also make ‘mistakes’ on purpose.
A pan-cancer analysis of the microbiome in metastatic cancer
Characterization of microbiome genomes at the species level in over 4,000 metastatic tumor biopsies identifies the distribution and diversity features of tumor-resident bacterial DNA at…
Harvard Nutritionist: The No. 1 nutrient you need for a healthy brain
There’s no one-size-fits-all way to prevent dementia, but a key nutrient found in salmon, sesame seeds, walnuts, and more can help keep your brain sharp…
Wafik S. El-Deiry: The published version of our paper that’s out as a preprint – OncoDaily
Wafik S. El-Deiry: The published version of our paper that’s out as a preprint / Brown University, cancer, COVID vaccines, David Gorski, Legorreta Cancer
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
Nature Communications – CDK4/6 inhibitors have improved outcomes for patients with ER+ breast cancer, however, those with loss of RB1 function often fail to respond.…
Single-Cell Untargeted Lipidomics Using Liquid Chromatography and Data-Dependent Acquisition after Live Cell Selection
We report the development and validation of an untargeted single-cell lipidomics method based on microflow chromatography coupled to a data-dependent mass spectrometry method for fragmentation-based…